Sandra assists companies avoid costly reimbursement and go-to-market mistakes by aligning regulatory, clinical, and commercial strategy with payer reality-early enough to protect valuation and capital efficiency. She serves as a fractional head of Market Access for select MedTech, digital health, and AI-enabled healthcare companies, typically post-seed through Series B.

Reimbursement risk is one of the most understood drivers of missed revenue forecasts, delayed adoption, capital inefficiency, and down-rounds and extended timelines. Sandra works with founders and investors to surface and resolve these risks before they become embedded in the business model.